Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Jaguar Health (NASDAQ:JAGX) announced that the first pediatric patient with microvillus inclusion disease (MVID) has entered the active treatment only, single-blind extension phase of its pivotal multicenter randomized double-blind crossover trial of liquid oral crofelemer as adjunctive therapy to parenteral support.
The extension will assess longer-term safety and efficacy to support planned NDA filing in mid-2027, subject to study completion and regulatory alignment. The trial spans the US, EU, and UAE, and crofelemer has orphan drug designation from FDA and EMA for MVID.
Jaguar Health (NASDAQ:JAGX) regained compliance with Nasdaq's minimum 500,000 publicly held shares requirement after third-party investors exercised pre-funded warrants on May 4, 2026.
The Nasdaq Hearings Panel granted an extension of the company's deadline to meet the $1.00 bid price rule to May 18, 2026, during which Jaguar must evidence a closing bid of at least $1.00 for 10 consecutive business days.
Jaguar Health (NASDAQ:JAGX) family company Napo Pharmaceuticals held a preliminary FDA discussion to evaluate Breakthrough Therapy Designation for oral liquid crofelemer as adjunctive therapy to parenteral support (PS) for pediatric intestinal failure due to microvillus inclusion disease (MVID).
Crofelemer showed preliminary proof of concept in two open-label pediatric MVID patients with meaningful reductions in weekly PS needs; initial long-term results accepted for presentation at ESPGHAN 2026. A pivotal randomized placebo-controlled MVID trial has completed enrollment. Orphan designations granted in US and EU for MVID and short bowel syndrome.
Jaguar Health (NASDAQ:JAGX) announced Neonorm Dog, a plant-based, non-prescription extension of its Neonorm franchise to support normal stool formation, gut hydration, and bowel health in dogs. The franchise already includes Neonorm Foal and Neonorm Calf and uses a standardized botanical extract from Croton lechleri.
Neonorm Dog will be sold through select online and animal health retail channels after final packaging and labeling are completed; Jaguar highlights its animal health strategy and recent statistically significant topline trial results for crofelemer in dogs.
Jaguar Health (NASDAQ:JAGX) reported statistically significant effectiveness from a pivotal field trial of crofelemer (conditionally approved Canalevia-CA1) for chemotherapy-induced diarrhea (CID) in dogs. Dogs treated twice daily showed an average daily stool regarded as normal after three days. Owner surveys: 83% found treatment effective; ~40% reported complete resolution. Comparator: 12.5% of owners reported improvement without CID treatments. Jaguar expects to file full trial data to support a full FDA approval and pursue scientific publication.
Jaguar Health (Nasdaq: JAGX) received a Nasdaq Hearings Panel extension to May 15, 2026, to demonstrate compliance with the $1.00 bid price rule and announced a 1-for-35 reverse stock split effective April 30, 2026. The company said post-split shares will trade on a split-adjusted basis under symbol JAGX and will use new CUSIP 47010C862. Stockholders of record will receive exchange instructions from Equiniti Trust Company; brokerage-held shares require no action. Fractional shares will be cash‑settled.
Jaguar Health (NASDAQ: JAGX) family company Napo announced acceptance of two late-breaking abstracts at ESPGHAN for liquid oral crofelemer treating pediatric intestinal failure (IF) from microvillus inclusion disease (MVID) and short bowel syndrome (SBS).
Company reports crofelemer was well tolerated, associated with reductions in parenteral support (PS) and gains in weight/height in treated pediatric patients; orphan drug designations exist in the US and EU and a pediatric randomized MVID trial completed enrollment with an NDA planned mid-2027.
Jaguar Health (NASDAQ:JAGX) announced that stockholders approved all five proposals at its Special Meeting held April 20, 2026. The proposals are described in the definitive proxy statement on Schedule 14A filed March 24, 2026. Stockholders can obtain the proxy and related SEC filings for free at the SEC website or the company website.
Jaguar Health (NASDAQ:JAGX) plans to leverage AI platforms to support development, commercialization, and healthcare delivery for crofelemer in intestinal failure (IF) including pediatric MVID.
Key points: an investigator-sponsored MVID program showed up to 37% reduction in parenteral support; Jaguar is pursuing Breakthrough Therapy designation and is seeking non-dilutive partner funding to accelerate approval and access.
Jaguar Health (NASDAQ:JAGX) will host an investor webcast on Friday, April 10, 2026 at 8:30 a.m. Eastern to discuss Q4 2025 financials and company updates.
Participant registration is available via the company’s registration link and a replay will be posted on Jaguar Health’s investor relations website.